** Shares of drugmaker Axsome Therapeutics AXSM.O rise 13.5% to $119.99 premarket
** Co says it has entered into a settlement agreement with Teva Pharmaceuticals TEVA.TA, resolving all patent litigation related to AXSM's depression drug Auvelity
** Under terms of agreement, AXSM to grant Teva license to sell generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity
** If no pediatric exclusivity is granted, AXSM to grant Teva license six months earlier - on or after September 30, 2038
** "This outcome is better than our base case, which assumed exclusivity through 2037"- brokerage Truist Securities
** Litigation resulted from regulatory submission by Teva to FDA seeking approval to market a generic version of Auvelity in the U.S. before expiration of applicable Axsome patents
** Stock had risen 6.3% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。